Cell Type-specific Adaptive Signaling Responses to KRASG12C Inhibition.
Hitendra S SolankiEric A WelshBin FangVictoria IzumiLancia DarvilleBrandon StoneRyan FranzeseSandip ChavanFumi KinoseDenis ImbodyJohn M KoomenUwe RixEric B HauraPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
Our phosphoproteomic study identified cell type-adaptive responses to KRASi. Markers and targets associated with ERBB2/3 signaling in epithelial subtype and with FGFR1/AXL signaling in mesenchymal subtype should be considered in patient enrichment schemes with KRASi.
Keyphrases